BNTC

Benitec Biopharma Inc.
  • Healthcare
  • Biotechnology
  • $419M market cap
Forecast run · Sep 14, 2026Upside rank 1467 of 3,136

Model Signal

ForecastQ Daily Probabilities
35.8%
43.0%
17.9%

Analyst Consensus

Recommendation2.14/5 Buy
Last price$12.19
Price target$20.50
Implied move+68.2%
Analysts7

ForecastQ Portfolios

BNTC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.